Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis

NCT02239562 is registered in ClinicalTrials.gov with Christopher O'Brien, MD as lead sponsor.

NCT NCT02239562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02239562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis
Lead sponsor
Christopher O'Brien, MD
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2014
Completion date
December 29, 2016
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hepatitis